What is Opdivo’s MOA (mechanism of action)?
Opdivo (nivolumab) is an immune checkpoint inhibitor. It works by blocking the PD-1 (programmed death-1) receptor on T cells. When PD-1 is blocked, T cells are less “turned off,” which can help them recognize and attack cancer cells [1].
How does blocking PD-1 translate into an anti-cancer effect?
Normally, the PD-1 pathway helps keep immune responses from damaging healthy tissue. Many tumors use this pathway to dampen T-cell activity. By inhibiting PD-1, Opdivo can restore T-cell function and enhance the immune system’s ability to target tumor cells [1].
Is Opdivo classified as a chemotherapy?
No. Opdivo is not a chemotherapy drug. It is an immunotherapy (a monoclonal antibody) that modulates immune signaling rather than directly killing rapidly dividing cells [1].
What happens if PD-1 is inhibited—what side effects does that raise?
Because PD-1 helps restrain immune activity, blocking it can lead to immune-related adverse events (where the immune system can also attack normal tissues). The most relevant details depend on the specific patient and treatment context [1].
What’s the difference between Opdivo and PD-L1 inhibitors?
Opdivo targets PD-1 on T cells. PD-L1 inhibitors target the PD-L1 ligand on tumor cells (and other cells). Both approaches interfere with the PD-1/PD-L1 pathway, but they act on different components of that immune checkpoint axis [1].
Sources:
1. https://www.opdivo.com/about-opdivo/how-opdivo-works.html